Abbott and St. Jude Medical re-up and expand their partnership to co-market coronary stents and cardiology devices; also, Thoratec, HeartWare to split the LVAD market?; Arrhythmia Research releases Q1 prelims; ETView Medical inks Taiwan distribution deal; DeHaier Medical in Chinese distribution deal with Timesco; Nephros licences filtration tech from Medica; Toshiba's Vital Images inks MR deal with Olea; and SurgLine launches subsidiary to partner with spine surgeons; plus, a Funding Roundup and analysts' ups and downs.

Abbott (NYSE:ABT) and St. Jude Medical (NYSE:STJ) are renewing and expanding an alliance to co-market their cardiovascular products, including Abbott's market-leading Xience coronary stent line.
The deal, which extends a pact the companies inked in 2008, also includes St. Jude's line of cardiac rhythm management, electrophysiology and cardiology products.
It will see Abbott and St. Jude jointly promote the other's product offerings to U.S. hospital customers, according to a press release, and includes a separate agreement giving Abbott U.S. distribution rights for St. Jude's hybrid Ilumien FFR/OCT platform and its RadiAnalyzer Xpress system.
Covidien champions positive results for the Barrett's esophagus ablation device it acquired along...
Illinois healthcare giant Abbott lands European regulatory approval for the Xience Xpedition 48,...
ALung Technologies says it's going for a Chinese regulatory nod for its Hemolung respiratory assist...
An attorney for a plaintiff suing robot-assisted surgical systems maker Intuitive Surgical says the...
The American Stroke Assn. and partners release the Spot a Stroke F.A.S.T. smartphone app to help...